{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-108983","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.834132+00:00","generated_at":"2026-06-09T23:56:38.988909+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone","bullets":["Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.","Interim analysis (60 events) on track for late 2023/early 2024; final analysis (80 events) targeted by end of 2024.","China partner 3D Medicines to begin REGAL enrollment in Q4 2023, triggering two milestone payments totaling $13.0 million.","3D Medicines has obtained all regulatory permits and set up 11 treatment centers in China; previously projected Q3 start delayed by supply-chain issues."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-108983","json":"https://secwatch.observer/filing/0001104659-23-108983.json","markdown":"https://secwatch.observer/filing/0001104659-23-108983.md","text":"https://secwatch.observer/filing/0001104659-23-108983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/0001104659-23-108983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/tm2328393d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:56:38.988909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}